{IMAGERIGHT:http://www.massdevice.com/sites/default/wp-content/uploads/checkup/090519_index.gif}Our Weekly Checkup takes the temperature of the 63 public medical device companies in the MassDevice Index. The index is weighted according to market capitalization, based on the number of shares outstanding for each company from its most recent quarterly report and each Friday’s closing share price.
The index for the week ended May 15 closed with a reading of 4.68, down nearly 18.5 percent compared with the prior week. It’s the second week the index has posted a decline (the week ended April 24 saw a 3.4 percent drop) and by far the largest move in either direction since we began tracking these companies in late March. The index, which has posted gains ranging from 1.89 percent to 7.74 percent over the seven weeks from April 3 through May 15, slipped 3.84 percent over that period due to last week’s poor performance.
The Weekly Checkup also compares Monday morning’s opening share prices with their value when the markets close Friday afternoon to calculate the biggest gainers and losers.
Here are the ten firms that posted the biggest share price gains and losses during the week ended May 8:
The five biggest gainers:
- NMT Medical Inc. +43.8% (open $0.80; close $1.15)
- Labspace +33.6% (open $23.64; close $31.58)
- Acusphere Inc. +22.6% (open $0.31; close $0.38)
- Dynamics Research Corp. +21.6% (open $7.12; close $8.66)
- HepaLife Technologies Inc. +11.1% (open $0.18; close $0.20)
And the five biggest losers:
- Osmetech -20.0% (open $3.75; close $3.00)
- Candela Corp. -16.8% (open $1.19; close $5.07)
- Cynosure Inc. -14.5% (open $15.27; close $12.14)
- Optos Inc. -14.5% (open $50.00; close $42.75)
- NxStage Medical Inc. -14.3% (open $2.30; close $1.97)
The checkup also takes a look at a different financial metric each week, ranking local players based their performance in that category.
This week we’re looking at research and development spending as a percentage of revenues. Here are the top 20 public medical device companies in Massachusetts, ranked by their R&D percentage spend as of the end of 2008:
- HeartWare International Inc.: 5,618% ($18.6 million on $331,799 in total revenues)
- Acusphere: 1,618% ($43.2 million on $2.7 million in total revenues)
- Pressure BioSciences Inc.: 212% ($1.8 million on $852,263 in total revenues)
- Biopure Corp.: 159% ($5 million on $3.1 million in total revenues)
- NMT Medical Inc.: 74% ($13.2 million on $17.9 million in total revenues)
- Implant Sciences Corp.: 67% ($3.5 million on $5.2 million in total revenues)
- Clinical Data Inc.: 55% ($18.6 million on $34 million in total revenues)
- Abiomed Inc.: 42% ($24.9 million on $58.9 million in total revenues)
- Hologic Inc.: 39% ($646.6 million on $1.67 billion in total revenues)
- Insulet Corp.: 36% ($13.1 million on $36.1 million in total revenues)
- Interleukin Genetics Inc.: 36% ($3.6 million on $10 million in total revenues)
- Vision-Sciences Inc.: 35% ($3.4 million on $10 million in total revenues)
- Palomar Medical Technologies Inc.: 20% ($17.7 million on $87.6 million in total revenues)
- iCad Inc.: 19% ($7.1 million on $37.5 million in total revenues)
- Amicas Inc.: 17% ($8.7 million on $50.4 million in total revenues)
- NeuroMetrix Inc.: 17% ($5.3 million on $31.1 million in total revenues)
- Aspect Medical Systems Inc.: 17% ($16.7 million on $99.3 million in total revenues)
- Caliper Life Sciences Inc.: 15% ($19.9 million on $134.1 million in total revenues)
- American Superconductor Corp.: 14% ($15.7 million on $112.4 million in total revenues)
- Boston Scientific Corp.: 13% ($1.1 billion on $8.1 billion in total revenues)
Source: Mergent Inc.
Disclaimer: MassDevice.com’s rankings do not reflect an opinion of companies’ health, prospects or viability. They are intended to provide a snapshot of publicly traded medical device companies and in no way constitute a recommendation to buy or sell any particular security, portfolio of securities, transaction or investment strategy.